Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $11.50.

RVNC has been the subject of a number of analyst reports. HC Wainwright reduced their price objective on shares of Revance Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 13th. Mizuho reduced their price objective on shares of Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Piper Sandler reiterated an “overweight” rating and set a $11.00 price objective (down from $20.00) on shares of Revance Therapeutics in a report on Friday, May 10th. The Goldman Sachs Group reduced their price objective on shares of Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Monday, May 13th. Finally, Needham & Company LLC reduced their price objective on shares of Revance Therapeutics from $18.00 to $12.00 and set a “buy” rating for the company in a report on Friday, May 10th.

Insider Activity

In related news, CFO Tobin Schilke sold 9,361 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $47,179.44. Following the completion of the transaction, the chief financial officer now owns 192,666 shares of the company’s stock, valued at $971,036.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Tobin Schilke sold 9,361 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $47,179.44. Following the completion of the transaction, the chief financial officer now owns 192,666 shares of the company’s stock, valued at $971,036.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Dustin S. Sjuts sold 9,211 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total transaction of $46,423.44. Following the completion of the transaction, the president now directly owns 167,550 shares of the company’s stock, valued at approximately $844,452. The disclosure for this sale can be found here. Insiders have sold a total of 29,089 shares of company stock valued at $143,642 over the last quarter. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Revance Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Opaleye Management Inc. purchased a new position in Revance Therapeutics in the 1st quarter worth approximately $3,862,000. California State Teachers Retirement System boosted its stake in shares of Revance Therapeutics by 9.8% in the 1st quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 8,668 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Revance Therapeutics by 28.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 69,361 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 15,496 shares in the last quarter. Capital World Investors boosted its stake in shares of Revance Therapeutics by 16.8% in the 1st quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company’s stock valued at $68,612,000 after purchasing an additional 2,006,459 shares in the last quarter. Finally, EntryPoint Capital LLC boosted its stake in shares of Revance Therapeutics by 109.4% in the 1st quarter. EntryPoint Capital LLC now owns 19,906 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,400 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Trading Down 5.1 %

NASDAQ:RVNC opened at $2.82 on Friday. The stock has a market capitalization of $294.55 million, a price-to-earnings ratio of -0.78 and a beta of 1.05. The firm has a fifty day simple moving average of $3.43 and a two-hundred day simple moving average of $5.34. Revance Therapeutics has a 12 month low of $2.57 and a 12 month high of $29.44.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $51.94 million for the quarter, compared to analyst estimates of $55.64 million. Equities analysts predict that Revance Therapeutics will post -1.83 earnings per share for the current fiscal year.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.